Top 10 Oncology Capital Raises in the U.S. – February 1st – 15th, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Izotropic, a research and development company specializing in cancer research and early detection for breast cancer, received CAD 455,000 of development capital through a private placement.
- Lixte Biotechnology Holdings, a biopharmaceutical company dedicated to improving patients’ lives by developing a drug class called Protein Phosphatase 2A inhibitors, received $1.05 million of development capital through a private placement.
Merger/Acquisition and Corporate
-
- Ambry Genetics, operator of a genetics diagnostics company intended to provide a comprehensive suite of genetic testing applications for inherited and non-inherited diseases, was acquired by Tempus AI for $600 million.
- Inka Health, provider of AI-driven analytics and multimodal data services intended for clinical research and drug development, was acquired by Onco Innovations for CAD 3 million.
Later Stage VC
-
- Axial Therapeutics, developer of a new class of biotherapeutics designed to treat neurological disorders, raised $19.38 million of venture funding.
- DepYmed, developer of potent inhibitors of the enzyme designed to offer therapeutics for cancer and rare diseases, raised $250,000 of venture funding.
- Seneca Therapeutics, developer of cell-based therapies designed to offer therapeutics and vaccines for solid cancer, raised $1.64 million of venture funding.
Early Stage VC
-
- Genomate Health, developer of a health technology platform designed to provide cancer treatment, raised $8.39 million of venture funding in the form of SAFE notes.
Angel, Seed, and Grant
-
- Permanence Bio, operator of a biotech research firm intended to find components to fight cancer, raised seed funding from Impatient Ventures.
- Vetigenics, operator of an animal health biotechnology company intended to improve the lives of companion animals through advanced science medicine, raised $6 million of seed funding.
#castleplacement #capitalraising #privateequity #venturecapital #investment #oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
